Valuing the benefits and harms of antenatal and newborn screening programmes in health economic assessments (VALENTIA)
Absorbing it all: A meta-ethnography of parents’ unfolding experiences of newborn screening
White AL. et al, (2021), Social Science and Medicine, 287
Methods for evaluating the benefits and harms of antenatal and newborn screening programmes adopted by health economic assessments: Protocol for a systematic review
Png ME. et al, (2021), BMJ Open, 11
Benefits and harms adopted by health economic assessments evaluating antenatal and newborn screening programmes in OECD countries: A systematic review of 336 articles and reports
Png ME. et al, (2022), Social Science and Medicine, 314
During pregnancy and the newborn period, women in the UK are offered a number of tests that tell them how likely it is that their babies have a number of genetic or physical conditions. These tests are called ‘screening’, and include the 12 week dating scan, 20 week anomaly scan, and the newborn blood spot (‘heel prick’) tests that look for conditions such as cystic fibrosis and sickle cell disease.
Providing thousands of screening tests and care for women and babies is very expensive to the NHS so it is important that the screening programmes represent good value for money. The process of comparing the costs and benefits of a screening programme is called a health economic assessment. It is one of the tools that the UK National Screening Committee (UKNSC, the body that makes recommendations to government on population screening) uses to decide whether to recommend a screening programme.
There is some concern about how accurately health economic assessments have incorporated and valued benefits and harms of current or new antenatal/newborn screening programmes. For example, it is challenging to value the benefits and harms of programmes that can lead decisions to terminate a pregnancy.
Our study will aim to investigate approaches to health economic assessment that have been used and provide recommendations about whether they are appropriate or if a new framework for economic assessment is needed.
NDPCHS project leads:
Other Oxford University leads
Oliver Rivero-Arias (Nuffield Department of Population Health, University of Oxford)
Jenny Shilton Osborne (Nuffield Department of Population Health, University of Oxford)
Miaoqing Yang (Nuffield Department of Population Health, University of Oxford)
Oliver Rivero-Arias, University of Oxford
Lisa Hinton, THIS Institute, University of Cambridge
Sian Taylor-Phillips, University of Warwick
Felicity Boardman, University of Warwick
Anne-Marie Slowther, University of Warwick
Jane Fisher, Antenatal Results and Choices
Baskaran Thilaganathan, St George's University Hospital NHS Foundation Trust
Sam Oddie, Bradford Institute for Health Research
Louise Locock, University of Aberdeen
January 2020 – September 2022
National Institute for Health Research (Health Technology Assessment Programme)